Trial Profile
Pilot Study to Assess the Role of Immune Activation and Apoptosis as a Marker for Treatment Intensification With Raltegravir in Hiv-Infected Patients on Antiretroviral Therapy With Long-Term Viral Suppression and Unfavourable Immunologic Response (Discordant Patients: v+i-).
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 24 Dec 2021
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; HIV protease inhibitors; Non-nucleoside reverse transcriptase inhibitors; Nucleoside reverse transcriptase inhibitors
- Indications HIV-1 infections
- Focus Therapeutic Use
- Acronyms DISCOR-RAL
- 26 Sep 2012 Primary endpoint 'CD4+-cell-count' has not been met.
- 26 Sep 2012 Results published in AIDS.
- 08 Mar 2012 Results presented at the 19th Conference on Retroviruses and Opportunistic Infections.